Author | Matthew H. Kulke, MD | OncLive

Author | Matthew H. Kulke, MD

Articles

Dr. Kulke on Emerging Cabozantinib Data for NETs

February 01, 2018

Video

Matthew H. Kulke, MD, Dana-Farber Cancer Institute, discusses the emerging data seen with cabozantinib (Cabometyx) for patients with neuroendocrine tumors (NETs).

x